BA (Hons), MSc
Inna joined the Health Economics Research Centre at the Nuffield Department of Population Health in October 2017 as a DPhil student. Her research investigates the trends, determinants and persistence of cholesterol-lowering drug use for the secondary prevention of cardiovascular disease in the UK and Europe, using NHS Scotland and UK Biobank data. Her research at Oxford is funded by a MRC, BHF and NDPH scholarship.
Prior to her doctoral research, Inna completed her MSc in Health Economics and International Health Policy at the London School of Economics and her BA (Hons) in International Economics with a Minor in International Law at the American University of Paris.
Quality of care for secondary cardiovascular disease prevention in 2009- 2017: population-wide cohort study of antiplatelet therapy use in Scotland
PREISS D. et al, (2023), BMJ Quality and Safety
Symptomatic SARS-CoV-2 Episodes and Health-Related Quality of Life.
Alacevich C. et al, (2023), Appl Health Econ Health Policy, 21, 761 - 771
Depression and anxiety during and after episodes of COVID-19 in the community.
Alacevich C. et al, (2023), Sci Rep, 13
Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017.
Thalmann I. et al, (2023), Heart, 109, 388 - 395
Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009-2017: a population-wide retrospective cohort study of Scotland
Thalmann I. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2328 - 2328